AngioDynamics Inc. Common Stock (ANGO)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

AngioDynamics is a medical device maker focused on cardiovascular disease and cancer, with products like Auryon and AlphaVac. I look for durable competitive advantages, consistent profits, and a margin of safety, and this company does not currently meet those tests. In fiscal 2026, the year ended 2026-05-31, filed revenue was $320.2M, but net income was -$36.7M and diluted EPS -$0.88. Fiscal 2025, the year ended 2025-05-31, was similar: revenue $292.5M and net loss $34.0M, or EPS -$0.83. The Lynch category is none because it lost money in each of the last four years. The latest filed quarter, fiscal Q1 2027 ended 2026-08-31, showed revenue of $80.9M, net loss of $7.1M, and EPS -$0.17; that is better than fiscal Q1 2026, ended 2025-08-31, when revenue was $75.7M, net loss $10.9M, and EPS -$0.26, so there is modest progress. Still, trailing free cash flow is only $508K, a 0.1% FCF yield on the $458.4M market cap. The balance sheet is a relative bright spot with D/E of 0.06, but ROE is -20.77% and ROCE -5.13%. At the $10.90 close on 2026-10-13, P/B is 2.66 and EV/EBITDA is 646.21. Altman Z of 1.07 and Piotroski 4/9 suggest fragility. FairStock score 34/100. I see a turnaround candidate, not a proven compounder; without self-sustaining profits, the current price lacks the margin of safety I require.

In plain English: AngioDynamics makes medical devices used in heart disease and cancer treatment. The business looks weak because it is still losing money and generates almost no spare cash. At the recent price, the shares do not look cheap compared with its losses and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-08-31) · fiscal Q3 2026 10-Q (period ended 2026-02-28) · fiscal Q2 2026 10-Q (period ended 2025-11-30) · fiscal Q1 2026 10-Q (period ended 2025-08-31) · FY2026 10-K (period ended 2026-05-31) · FY2025 10-K (period ended 2025-05-31) · FY2024 10-K (period ended 2024-05-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer